The Edinburgh Genome Foundry (EGF), one of the world’s leading bio-foundries, is collaborating with The Advanced Research and Invention Agency (ARIA) to accelerate biological research and unlock new discoveries that benefit everyone. The three-year programme will provide ARIA with access to and expansion of EGF’s automated laboratory… Read More
Novo Nordisk and Orbis Medicines have announced a strategic collaboration and license agreement to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. Under the terms of the agreement, Orbis Medicines is eligible to receive up to $1.4 billion in upfront and potential development and commercial milestone… Read More
Scottish deep-tech company Chemify has received £22 million ($29.7 million) in grants from Scottish Enterprise and the UK Government. The funding will support a significant expansion of Chemify’s capacity to digitise molecular discovery, synthesis and scale-up through a new Chemifarm. The grant package includes £16… Read More
AI start-up deepmirror has been awarded a Phase 2 Sovereign AI grant as part of Innovate UK’s support for British businesses building world-leading AI technologies. The grant will fund deepmirror’s data acquisition strategy in which it selects the experiments most likely to improve its molecular… Read More
Genomics drug discovery company OutSee has been awarded funding through Innovate UK’s Investor Partnership Grant, jointly provided by Innovate UK and Empirical Ventures. The grant will enable OutSee to conduct a pilot study for a prototype target validation sub-system, designed for initial triage of potential drug targets… Read More
The Cambridge Crystallographic Data Centre (CCDC) has launched the CCDC Innovation Fund, a new seed funding programme designed to support emerging companies developing innovative solutions in structural chemistry. The fund, backed by an initial commitment from the CCDC of up to £300,000, will provide early-stage support to start-ups and university spin-outs seeking to transform structural… Read More
Deep Origin’s docking and molecular dynamics (MD) simulations have successfully rationalised researchers’ work identifying a potent compound to switch on cell-death programmes in diffuse large B cell lymphoma (DLBCL). The study was led by researchers at Stanford University and the University of Texas MD Anderson Cancer Center. … Read More
AI-driven drug discovery depends on large-scale, information-rich biological datasets that capture how compounds perturb cellular systems across diverse conditions. Building these datasets requires scalable approaches that can combine phenotypic and molecular readouts in high-throughput screening workflows. In this webinar, hosted by DDW, Daniel Alpern, Chief Scientific Officer at… Read More
Partha Anbil, SVP, Life Sciences, at Coforge Limited, and Alex Kandybin, Founder of Quantum Wargaming, explore how quantum computing is… Read More
Steven Bulera, Corporate Vice President, Chief Scientific Officer: Safety Assessment, Charles River Laboratories, explores various use-cases of AI in improving drug discovery. It’s difficult, if not impossible, to escape the headlines and… Read More
AI-driven drug discovery depends on large-scale, information-rich biological datasets that capture how compounds perturb cellular systems across diverse conditions. Building these datasets requires scalable approaches that can combine phenotypic and molecular readouts in high-throughput screening workflows. In this webinar, hosted by DDW, Daniel Alpern, Chief Scientific Officer at… Read More
AI-driven drug discovery depends on large-scale, information-rich biological datasets that capture how compounds perturb cellular systems across diverse conditions. Building these datasets requires scalable approaches that can combine phenotypic and molecular readouts in high-throughput screening workflows. In this webinar, hosted by DDW, Daniel Alpern, Chief Scientific Officer at… Read More
Anthropic has launched Claude Science, an app that it says integrates the tools and packages that researchers most commonly use, produces auditable artifacts, and provides flexible access to computing resources. At the launch event, the company also announced that it will be using the product to pursue… Read More
AI-driven drug discovery depends on large-scale, information-rich biological datasets that capture how compounds perturb cellular systems across diverse conditions. Building these datasets requires scalable approaches that can combine phenotypic and molecular readouts in high-throughput screening workflows. In this webinar, hosted by DDW, Daniel Alpern, Chief Scientific Officer at… Read More
